Intravenous ketamine and progressive cholangiopathy in COVID-19 patients

Keta-Cov research group. Electronic address: vincent.mallet@aphp.fr; Keta-Cov research group

doi:10.1016/j.jhep.2021.02.007

Intravenous ketamine and progressive cholangiopathy in COVID-19 patients

J Hepatol. 2021 May;74(5):1243-1244. doi: 10.1016/j.jhep.2021.02.007. Epub 2021 Feb 19.

Authors

Keta-Cov research group. Electronic address: vincent.mallet@aphp.fr; Keta-Cov research group

Collaborators

Vincent Mallet¹, Kilian Bock², Paul Doumbe Mandengue¹, Nicolas Dufour³, Torsten Voigtlaender⁴, Jean-Damien Ricard⁵, Pierre Isnard⁶, Vincent Frochot⁷, Emmanuel Letavernier⁷, Lucile Moga⁸, Amandine Landrieux⁸, Pierre-Emmanuel Rautou⁸, Nathalie Pons-Kerjean⁹, Anaïs Vallet-Pichard¹, Laurent Chouchana¹⁰, Coralie Gernez⁵, Carole Burger¹¹, Anne Scemla¹¹, Christian de Tymoski¹², François Depret¹², Emmanuel Dudoignon¹², Lionel Lamhaut¹³, Rémi Flicoteau¹⁴, Géraldine Rousseau¹⁵, Jean-Paul Duong Van Huyen⁶, Jean-Michel Correas¹⁶, Heiner Wedemeyer², Stanislas Pol¹

Affiliations

¹ Université de Paris, AP-HP, Hôpital Cochin, DMU Cancérologie et spécialités médico-chirurgicales, Service d'Hépatologie, Paris, France.
² Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hannover, Germany; German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, France.
³ Centre Hospitalier René Dubos, 95300 Pontoise, France.
⁴ Dept. of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Str.1, 30625 Hannover, Germany.
⁵ Université de Paris, AP-HP, Hôpital Louis Mourier, DMU Esprit, Service de Réanimation Médico-Chirurgicale, Colombes, France.
⁶ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Imagina, Service d'Anatomo-Pathologie, Paris, France.
⁷ Sorbonne Université, AP-HP, Hôpital Tenon, DMU Biogem, Service de Physiologie, F-75020 Paris, France; INSERM, UMR S 1155, Hôpital Tenon, F-75020 Paris, France.
⁸ Université de Paris, AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU Digest, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Centre de recherche sur l'inflammation, Inserm, UMR 1149, Paris, France.
⁹ AP-HP, Hôpital Beaujon, Service de Pharmacie, DMU Prisme, Paris, France.
¹⁰ Université de Paris, AP-HP, Hôpital Cochin, DMU Prime, Service de Pharmacovigilance, Paris, France.
¹¹ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Carte, Service de Néphrologie et de Transplantation rénale, Paris, France.
¹² Université de Paris, AP-HP, Groupe Hospitalier St-Louis-Lariboisière, DMU Parabol, Département d'Anesthésie Réanimation et Centre de Traitement des Brûlés, Paris, France; FHU Promice, Paris, France; INI-CRCT, Nancy, France.
¹³ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, Department of Anesthesiology and Critical Care, Paris, France.
¹⁴ Université de Paris, AP-HP, Hôpital Saint Louis, DMU Prisme, Service de Biostatistique et Information Médicale, Paris, France.
¹⁵ Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Hôpital Pitié-Salpêtrière, DMU SAPERE - APHP Sorbonne Université, France.
¹⁶ Université de Paris, AP-HP, Hôpital Necker Enfants Malades, DMU Imagina, Service de Radiologie, Paris, France.

No abstract available

Keywords: COVID-19; Chemical and Drug Induced Liver Injury; Cholangiopathy; Cholangitis; Cholestasis, Intrahepatic; Ketamine.

Publication types

Letter

MeSH terms

Administration, Intravenous
Anesthetics, Dissociative / administration & dosage
Anesthetics, Dissociative / adverse effects
Bile Duct Diseases* / blood
Bile Duct Diseases* / chemically induced
Bile Duct Diseases* / pathology
Bile Duct Diseases* / therapy
Biopsy / methods
COVID-19* / epidemiology
COVID-19* / therapy
Dose-Response Relationship, Drug
Drug Monitoring / methods*
Duration of Therapy
End Stage Liver Disease* / chemically induced
End Stage Liver Disease* / diagnosis
End Stage Liver Disease* / mortality
Female
France / epidemiology
Germany / epidemiology
Humans
Ketamine* / administration & dosage
Ketamine* / adverse effects
Liver Function Tests / methods
Male
Middle Aged
Outcome and Process Assessment, Health Care
Respiration, Artificial / methods*
SARS-CoV-2

Substances

Anesthetics, Dissociative
Ketamine